Sections
Shortcuts
Business

Acetylon draws Celgene investment, possible buyout

This is a summary. To read the whole story subscribe to BostonGlobe.com

Acetylon Pharmaceuticals of Boston, developer of small molecule drugs for multiple myeloma and other cancers, plans to announce Monday a $100 million investment by biotech giant Celgene Corp. that could lead to a $1.1 billion acquisition.

Acetylon, whose founders are affiliated with the Dana-Farber Cancer Institute, Harvard Medical School and Massachusetts General Hospital, plans to use some of the money to fund continuing development of its leading drug candidate, ACY-1215, which targets myeloma. Three other cancer treatments also are in the works. In exchange for the investment, Celgene will receive an exclusive option to buy Acetylon for between $500 million and $1.1 billion, depending on future milestones. The new investment follows a $15 million equity stake Celgene took in Acetylon in 2012.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Sections
Shortcuts

Share